Tag Archives: PFC

Business, Finance, Occupation & Industry

Fairchild Semiconductor's Power Supply WebDesigner Now Provides CCM, Non-Isolated PFC Buck and Buck

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Fairchild Semiconductor’s Power Supply WebDesigner Now Provides CCM, Non-Isolated PFC Buck and Buck LED Driver Designs in Under a Minute

New Modules Provide Optimal Design with Complete Schematics, Inductor Design and Bill of Materials

SAN JOSE, Calif.–(BUSINESS WIRE)– Fairchild Semiconductor (NYS: FCS) , a leading global supplier of high performance power and mobile semiconductor solutions, has enhanced Power Supply WebDesigner – an online design and simulation tool that provides complete designs in under a minute – to include complete continuous conduction mode (CCM), non-isolated active PFC buck and buck LED driver designs.

From user-specified design inputs, the Power Supply WebDesigner (PSW) tool allows designers to choose all the components used in a design or have the tool automatically recommend the design values – providing Fairchild part numbers where applicable. PSW can automatically recommend design values, or allows the user to evaluate their own component choices.

While using the tool, designers can accept default recommended values, or spend time optimizing the important details to their unique design needs. Designers can get quick, accurate estimates on design performance, and refine design choices as they go. The tool also allows them to spend the time to perform detailed simulation analysis and learn the insights of how their design and its hardware prototype will work with higher degree of confidence.

When a design is complete, PSW creates a BOM which can be sent to their procurement department or instantly procure the components online, saving time on documentation or sourcing parts elsewhere. Additionally, they can save their design for future reference or pass the design on to other engineers.

Using the Power Supply WebDesigner tool provides the inexperienced designer a quick guided design, while the experienced designer can take their requirements and further customize critical design factors.

Updates:

  • Fairchild’s latest CCM buck and non-isolated PFC buck LED drivers are added options for PSW users, supporting Fairchild’s family of LED drivers.
  • First-available LED online tool designed to help design EMI filters, predict power factor (PF) and total harmonic distortion (THD).
  • PSW features have been extended to include the special driver requirements of low power (≤ 20W) …read more
    Source: FULL ARTICLE at DailyFinance
Science & Technology

Researchers utilize atomic layer etch analysis to accelerate development of green chemistries

Leave a comment

Researchers sponsored by Semiconductor Research Corporation (SRC) today announced development of a modeling process designed to simulate atomic-level etching with chemicals that are effective alternatives to widely used perfluorocarbon (PFC) gases. The novel approach under way at the University of California, Los Angeles (UCLA) will identify and evaluate green plasma chemistries for processing emerging memory/logic devices and through-silicon-via (TSV)-enabled technologies for the semiconductor industry. …read more
Source: FULL ARTICLE at Phys.org

Business, Finance, Occupation & Industry

Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2013

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2013

MORRISVILLE, N.C.–(BUSINESS WIRE)– Oxygen Biotherapeutics, Inc. (NAS: OXBT) , a development stage biomedical company focused on developing oxygen-carrying intravenous and topical products, today announced financial results for the three and nine month periods ending January 31, 2013.

Third Quarter 2013 Financial Snapshot

  • Cash and cash equivalents were $0.8 million at January 31, 2013.
  • Net product sales from Dermacyte® were $2,900 for the third quarter of 2013 compared to $4,700 for the three months ended January 31, 2012.
  • Revenue earned under our U.S. Army research grant increased to $221,051 for the third quarter of 2013 compared to $146,101 for the three months ended January 31, 2012.
  • Net loss from operations decreased 16% for the third quarter of 2013 to $1.6 million compared to $1.9 million for the three months ended January 31, 2012.
  • Net cash used for operating activities decreased to $700,000 for the third quarter of 2013 compared to $2.3 million for the three months ended January 31, 2012.

“Activities during our most recent quarter related to three primary and time consuming achievements needed to resume our Phase IIb traumatic brain injury studies abroad, to further our preclinical studies designed to elaborate the safety profile of Oxycyte, our leading drug candidate, and capital raising activities that resulted in securing enough cash to finance activities to help us achieve the next major milestones necessary to drive our company forward, ” said Michael Jebsen, Interim Chief Executive Officer, Chief Financial Officer and President.

Oxygen Biotherapeutics reported net revenue of $222,388 and $1,009,356 for the three and nine months ended January 31, 2012, respectively compared to $148,262 and $268,294 for the same periods in the comparable periods in fiscal 2012. This increase is primarily due to government grant revenue earned under the U.S. Army-funded grant awarded to the company in June 2011 to conduct preclinical studies for Oxycyte® perfluorocarbon (PFC) emulsion.

These preclinical studies are designed to address safety concerns expressed by the U.S. Food and Drug Administration (FDA)and to develop a more robust and comprehensive safety profile for Oxycyte. The results will be used to respond to …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ON Semiconductor Addresses Modern Power Design Challenges at Applied Power Electronics Conference 20

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ON Semiconductor Addresses Modern Power Design Challenges at Applied Power Electronics Conference 2013

Cutting-edge digital AC-DC PWM controllers, motor drivers and IGBTs to be demonstrated by the company at industry’s premier power electronics show

LONG BEACH, Calif.–(BUSINESS WIRE)– ON Semiconductor (Nasdaq: ONNN), driving innovation in energy efficiency, will showcase its latest power efficient product advances at APEC 2013, March 17-21, 2013, in Long Beach, California. The new devices are designed for boosting performance and simplifying the design of offline power supplies, AC lighting infrastructure and motor control systems.

Targeted for high efficiency, compact, switch-mode power supplies for power adaptors, the NCP1937is a quasi-resonant (QR) flyback controller device with power factor correction (PFC). This is the first AC-DC device utilizing a hybrid digital core architecture enabling higher efficiency, increased flexibility and easier system design implementation. The device incorporates all the features necessary for building a robust and compact PFC stage in combination with a QR flyback stage, while minimizing the number of external components. The quasi-resonant current-mode flyback stage features a proprietary valley-lockout circuitry, ensuring stable valley switching. It has wide voltage range spanning 9 volts (V) to 30 V, plus built-in over-voltage protection, and a skip mode operation which enables higher efficiency in light load conditions. The NCP1937 will be demonstrated in an 85 watt (W) Notebook Adapter showcasing the industry’s leading <10 milliWatt (mW) no load standby power.

The NCP1255/NCP1254 is a fixed frequencyPWM controller designed for applications requiring peak power capability. Offered in SOIC-8 and TSOP-6 packages, it operates with a fixed 65 kilohertz (kHz) switching frequency with the ability to scale the frequency up to 130 kHz based on output load requirements. In light load conditions with the power on the secondary side decreasing, the IC automatically folds back its switching frequency to a minimum level (26 kHz). The inclusion of adjustable over-power protection and adjustable brown-out protection functions make this device ideal for products requiring peak-power capabilities such as printers and ultrabooks. The NCP1255 will be demonstrated in a 15 W nominal 55 W peak power printer adapter.

For LED power supply applications, the high functional integration of theNCL30081 PWM controller IC minimizes the number of external components required for AC powered LED lighting designs. It operates in a quasi-resonant mode to enhance overall efficiency and provides precision regulation of the LED current from the primary side. Dispensing with the need for secondary side feedback control, as well as the associated optocoupler and …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast

–Special Meeting of Shareholders scheduled for April 26, 2013-

MORRISVILLE, N.C.–(BUSINESS WIRE)– Oxygen Biotherapeutics, Inc. (NAS: OXBT) today announced that the Company plans to report third quarter fiscal year 2013 financial results on Form 10-Q on Monday, March 18, 2013. Oxygen’s President and Chief Financial Officer Michael Jebsen will host a conference call and live webcast to discuss the results on Tuesday, March 19, 2013, at 11 a.m. EDT.

To access the live teleconference, dial (866) 277-1184 (U.S. and Canada) or (617) 597-5360 (international.) The participant pass code is 10084976. A live webcast will be available on our web site http://www.oxybiomed.com/investors.htm.

A replay of the webcast will be available on the Oxygen website, or by phone for a limited time. To access the replay by phone, call (888) 286-8010 (U.S. and Canada) or (617) 801-6888 (international). The pass code for the replay is 10065352.

In addition, the company announced that it will hold a Special Meeting of Shareholders on April 26, 2013. A preliminary proxy on Form Pre 14A was filed with the Securities and Exchange Commission on March 12. To access a copy of the Form Pre 14A, click here and then click the SEC Filings tab.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte® line of skin care cosmetics for the anti-aging market.

Oxygen Biotherapeutics, Inc.
Ellen Corliss, 919-855-2112
Senior Vice President, Corporate Communications & Investor Relations

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:

The article Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast originally appeared on Fool.com.

Try any of …read more
Source: FULL ARTICLE at DailyFinance